The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Currently, only 13 states cover GLP-1 drugs for obesity under Medicaid. But a new proposal announced by the Biden ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...